EC Number | Application | Comment | Organism |
---|---|---|---|
2.7.11.26 | medicine | GSK3 is a fundamental and central component of Fragile X syndrome pathology | Mus musculus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.26 | AR-A014418 | selective ATP-competitive inhibitor of GSK3 | Mus musculus | |
2.7.11.26 | lithium | - |
Mus musculus | |
2.7.11.26 | SB-216763 | selective ATP-competitive inhibitor of GSK3 | Mus musculus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.11.26 | ATP + protein tau | Mus musculus | - |
ADP + protein tau phosphate | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.7.11.26 | Mus musculus | - |
- |
- |
EC Number | Posttranslational Modification | Comment | Organism |
---|---|---|---|
2.7.11.26 | phosphoprotein | phosphorylation on serine-21 of GSK3alpha and serine-9 of GSK3beta greatly inhibits the activity of GSK3 | Mus musculus |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.7.11.26 | brain | - |
Mus musculus | - |
2.7.11.26 | brain cortex | - |
Mus musculus | - |
2.7.11.26 | cerebellum | - |
Mus musculus | - |
2.7.11.26 | hippocampus | - |
Mus musculus | - |
2.7.11.26 | striatum | - |
Mus musculus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.11.26 | ATP + protein tau | - |
Mus musculus | ADP + protein tau phosphate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.7.11.26 | glycogen synthase kinase-3 | - |
Mus musculus |
2.7.11.26 | GSK3 | - |
Mus musculus |
2.7.11.26 | GSK3alpha | isoform | Mus musculus |
2.7.11.26 | GSK3beta | isoform | Mus musculus |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.26 | ATP | - |
Mus musculus |